Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and
Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and
Barclays lowered the firm’s price target on Abbott to $140 from $141 and keeps an Overweight rating on the shares. The company’s strong operating performance and upside to Street estimates
ביצועים טובים של החברה ותוצאות טובות מהצפוי מוול סטריט לא הספיקו להתגבר על הדאגות בנוגע לבעיות משפטיות נוכחיות הקשורות למוצרי תזונה לילדים, אנליסט מודיע למשקיעים בדוח.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Labs (ABT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Abbott Labs (ABT)
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Labs, with a price target of $140.00. The company’s shares closed last Friday at $107.28.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
Abbott Labs has an analyst consensus of Strong Buy, with a price target consensus of $127.00, which is a 19.8% upside from current levels. In a report issued on April 17, Wells Fargo also maintained a Buy rating on the stock with a $133.00 price target.
See the top stocks recommended by analysts >>
Eli Lilly & Co (LLY)
Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co today and set a price target of $810.00. The company’s shares closed last Friday at $726.31.
According to TipRanks.com, Gould is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $845.60, a 12.9% upside from current levels. In a report issued on April 17, BMO Capital also initiated coverage with a Buy rating on the stock with a $900.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABT:
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN – Research Report), Abbott Labs (ABT – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report).
Terns Pharmaceuticals (TERN)
In a report issued on April 18, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Terns Pharmaceuticals, with a price target of $10.00. The company’s shares closed last Friday at $4.56, close to its 52-week low of $3.26.
According to TipRanks.com, Suvannavejh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Terns Pharmaceuticals with a $14.92 average price target, implying a 225.1% upside from current levels. In a report issued on April 3, Jefferies also assigned a Buy rating to the stock with a $22.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Abbott Labs (ABT)
In a report issued on April 18, Anthony Petrone from Mizuho Securities assigned a Hold rating to Abbott Labs, with a price target of $115.00. The company’s shares closed last Friday at $107.28.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Labs with a $127.07 average price target.
Arcutis Biotherapeutics (ARQT)
In a report issued on April 18, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $17.00. The company’s shares closed last Friday at $9.10.
According to TipRanks.com, Ear is a 3-star analyst with an average return of
Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.40, implying a 75.2% upside from current levels. In a report issued on April 12, Needham also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TERN: